GiveBetter x New York City

Parker Family Health Center

Whole recipient; comprehensive clinical-care health scenario

Research time: 4 min on GPT-6 Astra Light
  • Research — reviewed programs, finances and impact evidence.

Updated: 2026-09-14

Donate

Summary

What do they do? Parker provides comprehensive free primary and specialty-linked care to uninsured, low-income Monmouth County residents. Its clinical portfolio includes chronic disease management, women's and children's health, mental health, medication access and a new dental partnership. The estimate covers the broad clinical cohort while charging all recipient operations plus explicit allowances for external medication and unrecognized volunteer resources.

Why we’re interested in this organization:

  • Current residency eligibility gives a clear NYC-MSA beneficiary boundary.

  • Original financial records distinguish recognized donations from resources outside the accounts.

  • The modeled pathway spans primary care and chronic disease management rather than treating a screening count as complete impact.

Our main reservations:

  • The total patient cohort is inferred from an approximate reported diabetes share, not a verified current unique count.

  • Clinical response, alternative-care substitution and gift additionality are judgments.

  • Longer-term prevention, new dental volume and wider policy effects remain incompletely priced.

What do you get for your dollar? $7.6M per better life: ten additional quality-adjusted life years in New York City. Whole-recipient expense plus explicit external medication and nursing allowances, for finite direct-clinical health among the provisional Monmouth medical cohort. Not total portfolio return: newer dental, longer-term prevention, childhood and policy effects remain unpriced..

Comprehensive clinical access and sustained care -> meaningful symptom/function improvement across unique patients -> finite discounted QALYs. The central inferred 1,368-person cohort becomes 171 additional clinical-access equivalents after a and b; 42.75 are modeled utility responders. Full resource cost is $14,063.95 per additional patient equivalent and $56,255.81 per responder before utility integration. These are not observed unique cohorts or measured treatment successes.

1. What do they do?

The recipient is Parker Family Health Center Inc., EIN 22-3619518. Its current rules require Monmouth County residency, no medical insurance and income below 300% of the federal poverty level. The whole clinic includes primary care, chronic disease management, women's and children's care, mental health, medication assistance and specialist referrals. Monmouth County is inside the official NYC MSA; the estimate does not mistakenly classify the clinic as outside New York because its address is in New Jersey. Current eligibility and services

2. Monitoring and information sharing

FY2024 Part III reports 342 diabetic patients and describes diabetes as affecting approximately one quarter of patients. Dividing these gives a provisional 1,368-person cohort, not an independently reported unique-patient total. Women receiving care, children and screening counts can overlap and are not added. Prescription-assistance medication valued at $1.3 million is also an activity/resource measure, not a QALY gain. Original operating narrative

The current site reports a June 2026 dental-clinic opening at Brookdale and participation in a health-access workgroup. These show expansion and policy engagement, but no verified new dental patient-year yield or causal policy result is appended to the older medical cohort. Current volume could be higher or lower; the sensitivity changes the provisional patient denominator. Current operations

3. Qualitative assessment

Comprehensive clinical engagement is the strongest currently modelable material pathway: treating uncontrolled chronic illness, obtaining medication, supporting mental health and coordinating needed specialty care. The short-run health scenario spans the whole provisional clinical cohort rather than a small screening subset. Clinical access can matter, but access alone does not guarantee large physical-health improvements. The Oregon randomized insurance experiment increased care and reduced depression and financial strain without significant improvement in several measured physical-health markers over two years. It informs caution, not a directly transferable Parker QALY coefficient. External clinical evidence

Longer-term cardiovascular prevention, cancer outcomes, dental pain relief among newly added patients, children's development and policy effects may materially change total return. They are not silently valued at zero, but available follow-up cannot support adding separate lifetimes to this one-year clinical model. The result is a broad direct-clinical health estimate, not a complete social-return ranking.

4. What do you get for your dollar?

The resource-adjusted conditional direct-clinical price is approximately $7.64 million per 10 MSA QALYs, not measured complete portfolio return.

The provisional patient cohort is 342 divided by the reported approximate quarter with diabetes. Holding that older cohort constant is an explicit current-volume assumption. The central model assumes 25% obtain an incremental 0.1 health-utility improvement, decaying at a 0.5 annual rate and ending after one year, before 50% alternative-care substitution and a 25% ordinary funding response. A 0.001-QALY harm allowance per attributable patient accounts for small treatment burdens and adverse effects. These are subjective priors, not Parker follow-up measurements. No additional mortality benefit or repeat annual cohort is appended.

The full annual resource numerator is $2,404,936: $1,954,936 reported gross operating expense, plus $325,000 for medication-assistance resources and $125,000 for potentially unrecognized nursing resources. The former is 25% of the reported $1.3 million medication value; the latter assumes 25% of the reported 10,000 annual clinical-volunteer hours are unrecognized, valued at $50/hour. These adjustments are resource-value judgments, not new invoices or evidence that cash gifts purchase retail-price drugs. Recognized medical services are not added again. The high-resource case uses the full reported medication value and a larger nursing allowance.

The central local share is 100% for eligible Monmouth medical patients, with 95% tested for exceptional/referral leakage. The positive range varies unique cohort size, clinical response, durability and additionality. Complete substitution yields zero; no improvement with treatment harm gives negative QALYs. An operating-growth case charges 25% more operating cost without assuming extra patients. The donor-response discount appears once, not once per treatment or funding source.

Native bridge: the central 1,368-person inferred cohort becomes 171 additional clinical-access equivalents and 42.75 utility responders. Full resource cost is approximately $14,064 per additional patient and $56,256 per responder. The finite model assumes survival over its short benefit window rather than including a separate mortality hazard; no survival gain is claimed. Adding a 0.02 annual competing-mortality hazard to the central utility integral lowers net QALYs from 3.1480 to 3.1179. The effect-waning rate is not itself an observed mortality rate. A separate age/condition survival model would be needed before materially extending the horizon.

Model, assumptions and sensitivity

Entire recipient gross annual operations plus central allowances for external medication-assistance and unrecognized nursing resources. Actual annualExpenses remain reported gross accounting totals, distinct from the resource-adjusted model numerator.

g=1 for the medical cohort because current eligibility requires Monmouth residence; 95% leakage scenario retained. New dental and statewide policy effects are not assigned a speculative local yield.

C=C0+M*w+H*s*k; N=(D/share)*f; v=rho+ln(1+d); A=(1-exp(-v*T))/v; Qall=N*a*b*(p*u*A-h); QMSA=g*Qall; price10=10*C/QMSA if positive.

C0
1954936 USD reported recipient gross annual expense (observed). Original current gross cost, including event addback. [return2024] [schedule2024]
M
1300000 USD reported medication-assistance value (observed). Reported $1.3m assistance value, not acquisition cost; w explicitly adjusts. [return2024] [schedule2024]
w
0.25 resource-value fraction of reported medication value (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
H
10000 reported annual clinical-volunteer hours, rounded lower reference (observed). Narrative says more than 10,000 annual volunteer hours; 10,000 used as a rounded reference, not verified payroll. [return2024] [schedule2024]
s
0.25 unrecognized nursing fraction of volunteer hours (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
k
50 USD resource value per nursing hour (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
D
342 reported diabetic patients (observed). 342 patients in FY2024 narrative; no additional cohorts summed. [return2024] [schedule2024]
share
0.25 approximate diabetes share of patients (judgment). Approximately one quarter in original narrative; inferred total is approximate, not a measured unique count. [return2024] [schedule2024]
f
1 current cohort transfer fraction (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
p
0.25 meaningful clinical response fraction (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
u
0.1 utility gain among responders (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
rho
0.5 annual effect waning rate (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
T
1 maximum benefit years (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
a
0.5 care additionality fraction (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
b
0.25 funding-response fraction (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
h
0.001 QALY treatment burden per attributable patient (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
g
1 MSA benefit fraction (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]
d
0.03 annual discount rate (judgment). Explicit judgment; not source-calibrated local causal estimate. [patients] [audit] [clinical]

Broad direct-clinical health scenario: Cost: $2.4M; New York City QALYs: 3.1479955910350492; all-population QALYs: 3.1479955910350492. {"C0":1954936,"M":1300000,"w":0.25,"H":10000,"s":0.25,"k":50,"D":342,"share":0.25,"f":1,"p":0.25,"u":0.1,"rho":0.5,"T":1,"a":0.5,"b":0.25,"h":0.001,"g":1,"d":0.03}

Small response and substantial alternative care: Cost: $2.4M; New York City QALYs: 0.01423481660536924; all-population QALYs: 0.014984017479336044. {"C0":1954936,"M":1300000,"w":0.25,"H":10000,"s":0.25,"k":50,"D":342,"share":0.35,"f":0.75,"p":0.1,"u":0.03,"rho":0.5,"T":0.5,"a":0.25,"b":0.1,"h":0.0005,"g":0.95,"d":0.03}

Larger clinical response and sustained benefit: Cost: $2.4M; New York City QALYs: 69.96336879631968; all-population QALYs: 69.96336879631968. {"C0":1954936,"M":1300000,"w":0.25,"H":10000,"s":0.25,"k":50,"D":342,"share":0.2,"f":1.2,"p":0.4,"u":0.15,"rho":0.25,"T":2,"a":0.75,"b":0.5,"h":0.001,"g":1,"d":0.03}

Complete funding substitution: Cost: $2.4M; New York City QALYs: 0; all-population QALYs: 0. {"C0":1954936,"M":1300000,"w":0.25,"H":10000,"s":0.25,"k":50,"D":342,"share":0.25,"f":1,"p":0.25,"u":0.1,"rho":0.5,"T":1,"a":0.5,"b":0,"h":0.001,"g":1,"d":0.03}

No clinical benefit with treatment burden: Cost: $2.4M; New York City QALYs: -0.855; all-population QALYs: -0.855. {"C0":1954936,"M":1300000,"w":0.25,"H":10000,"s":0.25,"k":50,"D":342,"share":0.25,"f":1,"p":0,"u":0.1,"rho":0.5,"T":1,"a":0.5,"b":0.25,"h":0.005,"g":1,"d":0.03}

Full reported medication value and larger nursing resources: Cost: $3.6M; New York City QALYs: 3.1479955910350492; all-population QALYs: 3.1479955910350492. {"C0":1954936,"M":1300000,"w":1,"H":10000,"s":0.5,"k":75,"D":342,"share":0.25,"f":1,"p":0.25,"u":0.1,"rho":0.5,"T":1,"a":0.5,"b":0.25,"h":0.001,"g":1,"d":0.03}

Higher operating cost with unchanged outcomes: Cost: $2.9M; New York City QALYs: 3.1479955910350492; all-population QALYs: 3.1479955910350492. {"C0":2443670,"M":1300000,"w":0.25,"H":10000,"s":0.25,"k":50,"D":342,"share":0.25,"f":1,"p":0.25,"u":0.1,"rho":0.5,"T":1,"a":0.5,"b":0.25,"h":0.001,"g":1,"d":0.03}

Reported recipient cost only; external resources excluded: Cost: $2.0M; New York City QALYs: 3.1479955910350492; all-population QALYs: 3.1479955910350492. {"C0":1954936,"M":1300000,"w":0,"H":10000,"s":0,"k":50,"D":342,"share":0.25,"f":1,"p":0.25,"u":0.1,"rho":0.5,"T":1,"a":0.5,"b":0.25,"h":0.001,"g":1,"d":0.03}

Counterfactual: Other safety-net clinics, public insurance eligibility, charity care, pharmacy assistance and existing donors continue. a represents care substitution and b the additional scale supported by ordinary funds; both applied only once.

Attribution: One provisional clinical cohort avoids double counting women, children, diabetic patients and screening visits. Conditional response is net clinical improvement, not service completion. No separately added future mortality or policy effect.

Broad first-year clinical-health scenario with explicit inferred cohort and clinical priors. External-resource valuations are not observed acquisition costs. Major longer-term and new-program pathways remain incomplete, so this is not total portfolio return.

Sensitivity

  • Small response and substantial alternative care: 1689474523 USD per 10 MSA QALYs.
  • Larger clinical response and sustained benefit: 343742 USD per 10 MSA QALYs.
  • Complete funding substitution: no finite positive-benefit price.
  • No clinical benefit with treatment burden: no finite positive-benefit price.
  • Full reported medication value and larger nursing resources: 11530944 USD per 10 MSA QALYs.
  • Higher operating cost with unchanged outcomes: 9192103 USD per 10 MSA QALYs.
  • Reported recipient cost only; external resources excluded: 6210098 USD per 10 MSA QALYs.

Unresolved inputs

  • Current unique medical and dental patient cohorts, overlap and address verification.
  • Comparative clinical outcomes, persistence and longer-term vascular/cancer prevention.
  • Current unrestricted capacity response despite reserves and partner resources.
  • Full FY2024 audit detail reconciling donated services and actual resource value of external medications and nursing.
  • New dental-program cost, volume and incremental benefit relative to alternative care.

5. Funding and previous grants

FY2024 original gross expense is $1,954,936 = Part IX $1,917,459 + $37,477 separately netted event expense; Schedule D identifies exactly that difference to audit expense. FY2023 is $2,155,804 = $2,106,998 + $32,006 events + $16,800 employee-retention-credit filing fee separately reconciled. FY2022 is $1,682,923 = $1,325,806 + $316,291 donated services + $40,826 events. The original FY2023–2022 audit confirms the two historical gross totals and describes unrecognized nursing services. Original audit FY2024 reconciliation

FY2024 Schedule M reports $433,394 medical services, $15,000 equipment and $102,080 securities. Securities are funding, not another expense; capital equipment is not fully expensed on top of depreciation. The Part III medication-assistance value exceeds reported noncash medical contributions and is treated as an external-resource allowance with explicit valuation uncertainty. Noncash schedule

FY2024 reports $391,269 government grants, $8,891,536 net assets including $583,227 restricted, and $2,446,502 cash/savings. Much wealth is not freely spendable cash, and prior capital fundraising does not establish an operating gap. Current private gifts, public grants, pharmacy partners, volunteers and other safety-net providers remain in the counterfactual; an unrestricted donation is not assumed to create one-for-one additional treatment.

FY2024 Part IX allocates $1,671,157 to programs, $167,743 to management and $78,559 to fundraising; adding the $37,477 event expense reconciles gross cost. External medication and nursing allowances are separate from this accounting split. Current NJ guidance says some non-citizens lose FamilyCare eligibility after September 30, 2026, while most are unaffected, including children under 19 and several other groups. Cover All Kids remains an alternative for income-eligible children regardless of immigration status. Parker’s medical eligibility excludes insured and publicly eligible patients. Thus changes may increase adult need but do not justify assuming that every uninsured child lacks a public option, or that new demand automatically creates cash-responsive appointments.

Annual expenses

Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.

  • FY 2022: $1.7M; Parker Family Health Center Inc., EIN 22-3619518, 12-month period, Accrual gross recipient expense, including recognized donated services and separately netted event/filing expenses; external-resource model allowances shown separately.. Source
  • FY 2023: $2.2M; Parker Family Health Center Inc., EIN 22-3619518, 12-month period, Accrual gross recipient expense, including recognized donated services and separately netted event/filing expenses; external-resource model allowances shown separately.. Source
  • FY 2024: $2.0M; Parker Family Health Center Inc., EIN 22-3619518, 12-month period, Accrual gross recipient expense, including recognized donated services and separately netted event/filing expenses; external-resource model allowances shown separately.. Source

6. Sources

  1. FY2022 original IRS990. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  2. FY2022 original IRS990ScheduleD. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  3. FY2023 original IRS990. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  4. FY2023 original IRS990ScheduleD. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  5. FY2024 original IRS990. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  6. FY2024 original IRS990ScheduleD. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  7. Original FY2023–2022 financial audit and donated-resource notes. Parker Family Health Center / independent auditor. Published: not stated; retrieved: 2026-09-14.
  8. FY2024 original noncash schedule. Parker Family Health Center / IRS. Published: not stated; retrieved: 2026-09-14.
  9. Current patient scope and 2026 eligibility. Parker Family Health Center. Published: not stated; retrieved: 2026-09-14.
  10. Current dental expansion and health-access work. Parker Family Health Center. Published: not stated; retrieved: 2026-09-14.
  11. 2025–2026 service and community updates. Parker Family Health Center. Published: not stated; retrieved: 2026-09-14.
  12. Oregon randomized Medicaid experiment: clinical outcomes. Baicker et al. / NEJM. Published: 2013-05-02; retrieved: 2026-09-14.
  13. Ordinary donation route. Parker Family Health Center. Published: not stated; retrieved: 2026-09-14.
  14. September 2026 non-citizen eligibility changes and exceptions. NJ DMAHS. Published: not stated; retrieved: 2026-09-14.
  15. Current income-eligible child coverage. New Jersey. Published: not stated; retrieved: 2026-09-14.